MYRIAD GENETICS INC
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
MYGN$5.67-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss for the Years Ended
Consolidated Statements of Comprehensive Loss
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net loss attributable to Myriad Genetics, Inc. stockholders | $(365.9) | $(127.3) | $(263.3) |
| Change in unrealized loss on available-for-sale debt securities, net of tax | — | 0.1 | 1.2 |
| Change in foreign currency translation adjustment, net of tax | 0.8 | (3.0) | 2.1 |
| Reclassification adjustments for losses included in net loss, net of tax | — | — | 1.5 |
| Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax | 0.8 | 5.8 | 0.4 |
| Comprehensive loss | $(364.3) | $(124.4) | $(258.1) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.